Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Joep Perk, Guy De Backer, H. Gohlke et al. · European Heart Journal · 2012 · 8.5K citations · Full text

Medicine, Cardiology, Preventive Medicine +16

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Paul M. Ridker, Francisco Antônio Helfenstein Fonseca, Jacques Genest et al. · New England Journal of Medicine · 2008 · 6.6K citations · Full text

Medicine, Cardiology, Pharmacotherapy +10

Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

Paul M. Ridker, Francisco Antônio Helfenstein Fonseca, Jacques Genest et al. · Obstetrical & Gynecological Survey · 2009 · 3.7K citations

Medicine, Cardiology, Pharmacotherapy +10

Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B

Greg Brown, John J. Albers, Lloyd D. Fisher et al. · New England Journal of Medicine · 1990 · 2.2K citations · Full text

Medicine, Cardiology, Pharmacology +17

Lipoprotein(a) as a cardiovascular risk factor: current status

Børge G. Nordestgaard, M. John Chapman, Kausik K. Ray et al. · European Heart Journal · 2010 · 1.8K citations · Full text

Medicine, Cardiology, Clinical Cardiology +16